Sanofi presented data from the company’s Phase III LixiLan-G trial demonstrating that Soliqua/Suliqua showed superior decrease of average blood sugar level (HbA1c) after 26 weeks compared to other GLP-1 receptor agonists.
Insulin-dependent patients with T2D saw a significant drop in blood sugar levels after wearing Abbott’s continuous glucose monitoring system compared with those who use routine fingerstick testing.
Shares of Zealand Pharma A/S were up more than 2 percent after the company announced that dasiglucagon, a potential treatment for severe hypoglycemia, hit the mark in a Phase III study.
Danish drugmaker Novo Nordisk beat first-quarter 2019 operating profit forecasts, helped by higher sales of the company’s biggest new drug hope, a treatment for type 2 diabetes.
Combining 30 minutes of morning exercise with short walking breaks throughout the day may help control blood pressure.
For a while now there has been a heated debate surrounding hybrid and closed loop insulin systems.
One in seven people with type 2 diabetes may be needlessly testing their blood sugar at home several times a day, a U.S. study suggests.
The largest clinical trial so far to assess a new class of diabetes pills shows that AstraZeneca’s Farxiga can prevent heart failure and cut the risk of kidney problems in a broad range of patients.
Eli Lilly’s new two-in-one diabetes drug was successful in lowering blood sugar and reducing weight, sending the company’s shares to a record high and weighing on those of arch-rival Novo Nordisk.